Key Takeaways
- Volume-led 32% sales growth, mix shift accelerating: Revenue growth was driven by volume in Derivatives & Specialty, whose contribution jumped to 59% of sales from 46% a year ago.
- EBITDA up 65%, PAT nearly doubled: Operating leverage from new projects and higher utilization pushed PAT to INR81 crores and PAT margin to 13% from 8%.
- Balance sheet strengthening fast: Net debt-to-EBITDA improved to 1.4x from 1.8x, with total debt reduced to INR895 crores, while trailing ROCE reached 24%.
- Two world-scale expansions announced: CPVC capacity doubling to 150,000 TPA (world's largest) and ECH adding 50,000 TPA (India's largest), both targeting H1 FY27 commissioning.
- What to watch next quarter: The pace of chlorotoluene commissioning and customer approvals, the trajectory of ECU realizations after the September caustic price increase, and any detail on the new value chain being evaluated for the 100-acre land.
Volume Growth & Product Mix Shift
- Volume the primary engine: Sales growth of 32% YoY in Q2 and 37% in H1 came majorly from volume growth in value-added Derivatives & Specialty products, with realizations at or near bottom levels.
- Mix transformation underway: Revenue contribution from Derivatives & Specialty increased to 59% in Q2 FY25 from 46% in Q2 FY24, and management expects this share to rise further as all future capex is planned toward this business.
- Q2 volumes hit by seasonality: Volumes were lower QoQ because monsoon season is an off-season for some derivatives; Q3 is expected to be better, with the plant running above 80% capacity.
- H2 volume outlook positive: Second half volumes will be better than the first half, driven by capex already completed, though management declined to give a specific growth number.
- Realizations at a floor: Management sees realizations across products at "bottom of situation," with marginal QoQ changes in CPVC, ECH and other derivatives; any improvement from here would be an additional benefit.
Maulik Patel: "we are going to add further 75,000 tons per annum in CPVC resin to reach the total capacity of 150,000 tons per annum, and it will be the largest capacity plant in the world."
Chlor-Alkali & ECU Dynamics
- Caustic price recovery post-quarter: Domestic caustic soda prices moved upward at the end of September, so the benefit will reflect in Q3, not Q2; the QoQ fall in caustic realizations in Q2 was partly due to chlorine impact in India versus global markets.
- Chlorine drag deepened: Chlorine realizations were negative around INR6,000 to INR7,000 per ton in Q2, worsening from negative INR4,000 last quarter.
- ECU moving higher: ECU was around INR26,000 in Q2; after the caustic price increase and with chlorine weakening further, ECU moves to around INR30,000 to INR31,000.
- Captive chlorine consumption rising: Captive consumption increased from 70% to 79% as CPVC capacity expanded, with only 21% now sold in the merchant market; after the new CPVC and ECH projects, external chlorine sales will drop to about 10%.
- Structural chlorine advantage: Management framed the industry dynamic as caustic-driven, with chlorine derivative players needing to find ways to utilize chlorine internally; Epigral's expanding captive consumption insulates it from merchant chlorine volatility.
Maulik Patel: "the caustic soda is... driven by the caustic soda because of lack of propylene in India... definitely demand of caustic is going to go up and the chlorine derivative people need to find a way to utilize the chlorine internally."
Expansion Projects & Timelines
- CPVC capacity doubling: Adding 75,000 TPA to reach 150,000 TPA total, which management claims will be the largest single-location CPVC plant globally; commissioning expected in H1 FY27, with partial contribution that year and optimal run in FY28.
- ECH capacity addition: Adding 50,000 TPA, which will be the largest ECH plant in India; same H1 FY27 commissioning timeline, with major consumption expected in the domestic market where demand has nearly doubled in three years.
- Chlorotoluene value chain progressing: First block commissioned; second block to commission this quarter; last block in Q4, with full commissioning by Q4 FY25. Small orders expected in the initial quarter after commissioning, with actual volume pick-up in Q2 of next fiscal year.
- CPVC compound plant in trial phase: The 35 KT plant commissioned in June; products are under trial with various players, approved at a few levels but still in the testing phase at others; sizable contribution expected from Q4 onwards.
- New value chain under evaluation: A new chemistry, import-substitute product is being evaluated on the 100-acre land parcel; management expects to share more details by end of March.
- Capex bifurcation withheld: Management declined to split the INR780 crores capex plan between CPVC and ECH when asked by an analyst.
CPVC: Technology Moat & Pricing Risk
- Technology complexity as a barrier: Management emphasized that CPVC manufacturing is highly complex due to engineering challenges, extreme corrosiveness, and the infrastructure required for customer applications; approvals are difficult to secure despite the simple chemical formula.
- Anti-dumping duty on PVC creates a pass-through: The Commerce Ministry has announced an anti-dumping duty on suspension PVC, a key raw material for CPVC that management says is not manufactured in India; since CPVC realizations historically move in line with raw material costs, higher PVC prices will be reflected in CPVC realizations.
- Competitor sourcing contradiction flagged: An analyst pointed out that Reliance and DCW claim to use their own PVC for CPVC production, contradicting management's statement that suspension PVC is not made domestically; management responded only that it does not know whether domestic manufacturing will start in future.
- CPVC demand outlook strong: CPVC demand in India is expected to grow at double-digit rates, at similar or higher speed over the next 2 to 3 years.
Maulik Patel: "It is a very complex process. In terms of the engineering, it is very complex. In terms of the corrosiveness it is highly corrosive. And in terms of the customer also in the -- in terms of application, you need to have a lot of infrastructure in terms of the application also. So it is not that easy to manufacture."
Chlorotoluene & ECH: Domestic Market Build-Out
- ECH domestic mix transformed: Similar to the ECH experience where the company initially exported more and gradually built domestic customers, ECH now sells 80% domestically and 20% for export; long-term planning targets maximum domestic sales with around 20% export.
- ECH supply-demand gap expected: Management expects that two years down the line, a supply-demand gap will re-emerge in the ECH sector, supporting the expansion thesis.
- Chlorotoluene customer switching gradual: Customers need time to build confidence in a new supplier; switching will not happen overnight, with volume increase expected to be gradual.
- Chlorotoluene quality positioning: Management claims product quality will be at par with the best products available in the market, including LANXESS for the couple of products LANXESS manufactures.
- Chlorotoluene technology mix: A combination of technology partner input for some products and in-house development for others, with complexity arising from managing multiple products and isomer balance.
- Domestic focus for chlorotoluene: Long-term focus is Indian specialty chemical companies, with some portion going to Europe initially.
Margins, Costs & Guidance
- One-off other expense benefit: The INR20 to 21 crore sequential fall in other expenses in Q2 was a one-off, not a change in accounting practice.
- Full-year EBITDA margin guidance held at 25%: Despite H1 delivering 28% margins, management is sticking to 25% as conservative guidance, noting that in a normal situation margins can be in the 25% to 27% range.
- Revenue and PAT guidance maintained: Management confirmed it is moving in line with the INR2,500 to 2,600 crores revenue and INR300 to 350 crores PAT guidance.
- Volume growth guidance deflected: When asked for expected volume growth in H2 or the full year, management declined to give a specific number, saying only that the second half will be better than the first half.
Milind Kotecha: "first half we have done 28% kind of margin. And we said in a normal situation, we can be in the range of around 25% to 27%. But when I say 25%, it is for this year, it is for next year. So we are putting it that way."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| CPVC capacity expansion | 75,000 TPA added to reach 150,000 TPA total | Commission H1 FY27; optimal run FY28 |
| ECH capacity expansion | 50,000 TPA added, largest in India | Commission H1 FY27; optimal run FY28 |
| Chlorotoluene full commissioning | All blocks operational | Q4 FY25 |
| Chlorotoluene volume ramp-up | Small initial orders, actual pick-up | Q2 of next fiscal year |
| CPVC compound plant contribution | Sizable revenue contribution | Q4 FY25 onwards |
| New value chain details | Disclosure on import-substitute product for 100-acre land | By end of March |
| Full-year EBITDA margin | 25% (conservative guidance) | FY25 |
| Full-year revenue and PAT | INR2,500–2,600 crores revenue, INR300–350 crores PAT | FY25 |
| External chlorine sales reduction | From 21% currently to ~10% | After CPVC and ECH project commissioning |
Key Metrics
| Metric | Q2 FY25 |
|---|---|
| Revenue | ₹632 cr, +32% YoY |
| EBITDA | ₹178 cr, +65% YoY |
| EBITDA margin | 29%, vs 23% in Q2 FY24 |
| PAT | ₹81 cr, +111% YoY |
| PAT margin | 13%, vs 8% in Q2 FY24 |
| Sales volume growth | 6% YoY, flat QoQ |
| Capacity utilization | 83%, vs 77% in Q2 FY24 |
| Derivatives & Specialty revenue share | 59%, vs 46% in Q2 FY24 and 53% in Q1 FY25 |
| Total debt | ₹895 cr as on 30 Sep 2024, vs ₹963 cr as on 31 Mar 2024 |
| Net debt-to-EBITDA | 1.4x, vs 1.8x at end of Sep 2023 |
| ROCE (trailing 12 months) | 24%, vs 21% as on 30 Sep 2023; 28% excluding capital work in progress |
| Caustic utilization | ~75% |
| ECH utilization | ~85% |
| CPVC utilization | 65–70% |
| Chlorine captive consumption | 79%, up from 70% in Q2; 21% sold in market |
| ECU realization | ~₹26,000 in Q2; moved to ~₹30,000–31,000 post quarter-end |
| Full-year EBITDA margin guidance | 24–25% (conservative); H1 FY25 at 28% |